JP2018199675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018199675A5 JP2018199675A5 JP2018111785A JP2018111785A JP2018199675A5 JP 2018199675 A5 JP2018199675 A5 JP 2018199675A5 JP 2018111785 A JP2018111785 A JP 2018111785A JP 2018111785 A JP2018111785 A JP 2018111785A JP 2018199675 A5 JP2018199675 A5 JP 2018199675A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- amount
- cancer stem
- stem cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 description 69
- 238000000034 method Methods 0.000 description 67
- 201000011510 cancer Diseases 0.000 description 66
- 210000000130 stem cell Anatomy 0.000 description 57
- 108010055196 EphA2 Receptor Proteins 0.000 description 16
- 238000011275 oncology therapy Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 10
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 9
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 8
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 229940022399 cancer vaccine Drugs 0.000 description 4
- 238000009566 cancer vaccine Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000012831 peritoneal equilibrium test Methods 0.000 description 2
- 238000012636 positron electron tomography Methods 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612826P | 2012-03-19 | 2012-03-19 | |
| US61/612,826 | 2012-03-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501847A Division JP6502247B2 (ja) | 2012-03-19 | 2013-03-19 | 癌の状態を治療及びモニタリングする方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020101337A Division JP2020158518A (ja) | 2012-03-19 | 2020-06-11 | 癌の状態を治療及びモニタリングする方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018199675A JP2018199675A (ja) | 2018-12-20 |
| JP2018199675A5 true JP2018199675A5 (enExample) | 2019-02-07 |
Family
ID=49223299
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501847A Active JP6502247B2 (ja) | 2012-03-19 | 2013-03-19 | 癌の状態を治療及びモニタリングする方法 |
| JP2018111785A Pending JP2018199675A (ja) | 2012-03-19 | 2018-06-12 | 癌の状態を治療及びモニタリングする方法 |
| JP2020101337A Pending JP2020158518A (ja) | 2012-03-19 | 2020-06-11 | 癌の状態を治療及びモニタリングする方法 |
| JP2021213614A Pending JP2022058444A (ja) | 2012-03-19 | 2021-12-28 | 癌の状態を治療及びモニタリングする方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501847A Active JP6502247B2 (ja) | 2012-03-19 | 2013-03-19 | 癌の状態を治療及びモニタリングする方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020101337A Pending JP2020158518A (ja) | 2012-03-19 | 2020-06-11 | 癌の状態を治療及びモニタリングする方法 |
| JP2021213614A Pending JP2022058444A (ja) | 2012-03-19 | 2021-12-28 | 癌の状態を治療及びモニタリングする方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150079135A1 (enExample) |
| EP (4) | EP4361634A3 (enExample) |
| JP (4) | JP6502247B2 (enExample) |
| CA (2) | CA3223380A1 (enExample) |
| ES (3) | ES2699817T3 (enExample) |
| WO (1) | WO2013142477A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102686875B1 (ko) | 2016-10-07 | 2024-07-19 | 엔터롬 에스.에이. | 암 치료를 위한 면역원성 화합물 |
| WO2018065625A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Immunogenic compounds for cancer therapy |
| US11712465B2 (en) | 2016-10-07 | 2023-08-01 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| HUE060791T2 (hu) | 2018-04-11 | 2023-04-28 | Enterome S A | Antigén peptidek rák megelõzésére és kezelésére |
| US20210106652A1 (en) * | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE4121547A1 (de) | 1991-06-28 | 1993-01-14 | Daimler Benz Ag | Mehrschichtisolierfolie |
| ATE161190T1 (de) | 1991-10-07 | 1998-01-15 | Biogen Inc | Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| NZ528076A (en) | 2001-03-02 | 2005-09-30 | Medimmune Inc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules |
| US20030044406A1 (en) | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| FR2838742B1 (fr) * | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| KR20110094361A (ko) | 2003-04-11 | 2011-08-23 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| JP5129149B2 (ja) * | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
| US8343461B2 (en) * | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2526969A1 (en) * | 2006-09-07 | 2012-11-28 | Stemline Therapeutics, Inc. | Monitoring cancer stem cells |
| WO2008030538A2 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
| AU2008207945A1 (en) * | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
| JP2010190572A (ja) * | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| CA3066981A1 (en) * | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
-
2013
- 2013-03-19 WO PCT/US2013/032936 patent/WO2013142477A1/en not_active Ceased
- 2013-03-19 ES ES13763504T patent/ES2699817T3/es active Active
- 2013-03-19 EP EP23210443.0A patent/EP4361634A3/en not_active Withdrawn
- 2013-03-19 EP EP13763504.1A patent/EP2828664B1/en active Active
- 2013-03-19 EP EP20211725.5A patent/EP3855184B1/en active Active
- 2013-03-19 ES ES20211725T patent/ES2973957T3/es active Active
- 2013-03-19 CA CA3223380A patent/CA3223380A1/en active Pending
- 2013-03-19 JP JP2015501847A patent/JP6502247B2/ja active Active
- 2013-03-19 CA CA2902415A patent/CA2902415C/en active Active
- 2013-03-19 US US14/386,242 patent/US20150079135A1/en not_active Abandoned
- 2013-03-19 EP EP18189485.8A patent/EP3431997B1/en active Active
- 2013-03-19 ES ES18189485T patent/ES2887580T3/es active Active
-
2018
- 2018-02-12 US US15/894,121 patent/US20190031772A1/en not_active Abandoned
- 2018-06-12 JP JP2018111785A patent/JP2018199675A/ja active Pending
-
2020
- 2020-06-11 JP JP2020101337A patent/JP2020158518A/ja active Pending
-
2021
- 2021-12-28 JP JP2021213614A patent/JP2022058444A/ja active Pending
-
2022
- 2022-08-04 US US17/881,007 patent/US20230374152A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018199675A5 (enExample) | ||
| JP6672383B2 (ja) | 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール | |
| JP2020169198A (ja) | 治療方法及び組成物 | |
| KR102311590B1 (ko) | 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물 | |
| CN107249636B (zh) | 以ckap4作为靶分子的抗肿瘤剂 | |
| EP2971047A1 (en) | Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof | |
| US7744882B2 (en) | Soluble ErbB3 methods of detection and antibodies | |
| AU2010268979B2 (en) | New tumor marker | |
| WO2019065747A1 (ja) | 抗ｃｋａｐ４モノクローナル抗体 | |
| CN105393121B (zh) | 诊断癌症的方法 | |
| CN1862258A (zh) | 核仁素辅助的癌症诊断与治疗方法 | |
| EP1956032B1 (en) | Monoclonal antibody directed against cd166 and method for production thereof | |
| AU2005219322B2 (en) | Pharmaceutical Composition Comprising CXCR3 Inhibitor | |
| JP2004509357A (ja) | 予後インジケーター | |
| CN111378040B (zh) | 检测多种恶性肿瘤细胞的抗体及其应用 | |
| US8389684B2 (en) | Tumor biomarker | |
| JP5354634B2 (ja) | ヒトａｂｈ８タンパク質、それをコードする遺伝子、およびこれらの治療的又は診断的用途 | |
| EP2484693A1 (en) | Human serum amyloid-a3 antibody and use thereof | |
| JP6729917B2 (ja) | ＥｐｈＡ２ Ｎ末端フラグメント抗体 | |
| US20080267961A1 (en) | SOLUBLE ErbB3 AND TREATMENT OF CANCER | |
| JP7416445B2 (ja) | ブタにおけるｔ細胞の活性化度を評価する方法、ブタにおけるｔ細胞活性化を評価する剤、ブタｔ細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ | |
| WO2008066483A1 (en) | Use of nalp5 in methods for diagnosis and therapy of parathyroid related disorders | |
| WO2012133994A1 (ko) | Pauf 및 그의 결합 파트너를 상호작용을 이용한 암 치료제의 스크리닝 방법 | |
| WO2025025731A1 (zh) | 一种适用于免疫组化检测cd228的诊断抗体 | |
| AU2014203702B2 (en) | New tumor marker |